Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 2.380
-0.030 (-1.24%)
Aug 7, 2026, 4:10 PM AEST
Australian Clinical Labs Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 737.49 | 741.27 | 696.37 | 697.07 | 995.6 | 646.7 |
Revenue Growth | -0.51% | 6.45% | -0.10% | -29.98% | 53.95% | 31.83% |
Gross Profit Gross Profit Growth | 270.17 | 270.86 | 254 | 251.62 | 448.62 | 256.53 |
Operating Income Operating Income Growth | 68.65 | 68 | 62.55 | 65.22 | 273.98 | 128 |
Net Income Net Income Growth | 26.31 | 32.43 | 23.93 | 35.9 | 178.24 | 60.37 |
Earnings Per Share EPS Growth | 0.14 | 0.17 | 0.12 | 0.18 | 0.88 | 0.40 |
EPS Growth | -17.32% | 42.09% | -32.77% | -79.82% | 122.88% | 39.83% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 23.14 | 22.12 | 26.85 | 20.59 | 27.51 | 36.28 |
Total Debt Total Debt Growth | 315.11 | 290.38 | 308.9 | 316.32 | 262.38 | 303.85 |
Net Cash (Debt) Net Cash Growth | -291.98 | -268.26 | -282.05 | -295.73 | -234.87 | -267.57 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.56 | -1.41 | -1.41 | -1.47 | -1.17 | -1.76 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 164.57 | 182.8 | 159.59 | 143.68 | 284.09 | 153.86 |
Capital Expenditures CapEx Growth | -7.88 | -8.41 | -6.51 | -6.93 | -21.25 | -9.51 |
Free Cash Flow Free Cash Flow Growth | 156.7 | 174.39 | 153.09 | 136.75 | 262.84 | 144.36 |
Free Cash Flow Growth | -10.15% | 13.92% | 11.95% | -47.97% | 82.07% | 56.31% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | 36.63% | 36.54% | 36.48% | 36.10% | 45.06% | 39.67% |
Operating Margin | 9.31% | 9.17% | 8.98% | 9.36% | 27.52% | 19.79% |
Pretax Margin | 5.64% | 6.50% | 5.22% | 6.93% | 25.60% | 13.40% |
Profit Margin | 3.57% | 4.38% | 3.44% | 5.15% | 17.90% | 9.34% |
FCF Margin | 21.25% | 23.53% | 21.98% | 19.62% | 26.40% | 22.32% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 7, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.125 | 0.125 | 0.120 | 0.140 | 0.530 | 0.142 |
Dividend Per Share Growth | 2.00% | 4.17% | -14.29% | -73.58% | 271.93% | -1.38% |
Dividend Yield | 5.19% | 4.72% | 5.23% | 4.61% | 14.59% | 5.42% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 7, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 16.88 | 16.66 | 21.03 | 19.34 | 5.17 | 11.37 |
Forward PE | 13.75 | 13.94 | 13.83 | 15.92 | 9.64 | 7.42 |
P/FCF Ratio | 2.82 | 3.10 | 3.29 | 5.08 | 3.51 | 4.75 |
PS Ratio | 0.60 | 0.73 | 0.72 | 1.00 | 0.93 | 1.06 |